- Home
- LINC vs PRAX Comparison
LINC vs PRAX Comparison
Compare LINC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LINC
- PRAX
- Stock Information
- Founded
- LINC 1946
- PRAX 2015
- Country
- LINC United States
- PRAX United States
- Employees
- LINC N/A
- PRAX N/A
- Industry
- LINC Other Consumer Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- LINC Real Estate
- PRAX Health Care
- Exchange
- LINC Nasdaq
- PRAX Nasdaq
- Market Cap
- LINC 729.2M
- PRAX 599.7M
- IPO Year
- LINC 2005
- PRAX 2020
- Fundamental
- Price
- LINC $22.48
- PRAX $42.34
- Analyst Decision
- LINC Strong Buy
- PRAX Strong Buy
- Analyst Count
- LINC 4
- PRAX 11
- Target Price
- LINC $24.00
- PRAX $114.73
- AVG Volume (30 Days)
- LINC 277.1K
- PRAX 279.7K
- Earning Date
- LINC 08-07-2025
- PRAX 08-12-2025
- Dividend Yield
- LINC N/A
- PRAX N/A
- EPS Growth
- LINC N/A
- PRAX N/A
- EPS
- LINC 0.39
- PRAX N/A
- Revenue
- LINC $454,204,000.00
- PRAX $8,122,000.00
- Revenue This Year
- LINC $13.40
- PRAX N/A
- Revenue Next Year
- LINC $8.42
- PRAX $6,358.50
- P/E Ratio
- LINC $58.05
- PRAX N/A
- Revenue Growth
- LINC 15.24
- PRAX 270.02
- 52 Week Low
- LINC $10.31
- PRAX $26.70
- 52 Week High
- LINC $24.20
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- LINC 56.61
- PRAX 54.36
- Support Level
- LINC $22.16
- PRAX $41.64
- Resistance Level
- LINC $22.90
- PRAX $44.99
- Average True Range (ATR)
- LINC 0.84
- PRAX 2.55
- MACD
- LINC -0.18
- PRAX -0.11
- Stochastic Oscillator
- LINC 54.18
- PRAX 51.07
About LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.